Founded in 2006, NeoProteomics is dedicated to advancing systems biology and mass spectrometry through efficient and risk-minimizing solutions. The company offers specialized services in structural mass spectrometry and hydroxyl radical protein footprinting, catering primarily to pharmaceutical and biotech companies. Their core mission is to streamline the process of obtaining structural information for protein-based pharmaceuticals, thereby enhancing drug development and research.
NeoProteomics has established itself as a leader in its field, with notable experts contributing to its success. The company has achieved significant milestones in contract research, providing critical structural data that supports the development of new drugs. Their proprietary tools and methods have made a substantial impact on the efficiency and reliability of protein analysis in the biotech industry.
